Windtree Therapeutics Inc /De/ (WINTW) — SEC Filings
Windtree Therapeutics Inc /De/ (WINTW) — 50 SEC filings. Latest: 8-K (Dec 2, 2025). Includes 35 8-K, 4 10-Q, 4 S-1/A.
View Windtree Therapeutics Inc /De/ on SEC EDGAR
Overview
Windtree Therapeutics Inc /De/ (WINTW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 19, 2025: WINDTREE THERAPEUTICS INC /DE/ reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $(42,761) thousand, a substantial rise from $(4,554) thousand in the prior year. This was primarily driven by a $16,130 thousand impairment of intangible assets and a $(2
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 9 bearish, 41 neutral. The dominant filing sentiment for Windtree Therapeutics Inc /De/ is neutral.
Filing Type Overview
Windtree Therapeutics Inc /De/ (WINTW) has filed 35 8-K, 4 10-Q, 1 S-1, 4 S-1/A, 3 8-K/A, 2 SC 13G/A, 1 SC 13G with the SEC between Sep 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of WINTW's 46 recent filings, 9 were flagged as high-risk, 25 as medium-risk, and 12 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 thousand |
| Net Income | $(42,761) thousand |
| EPS | $(1.08) |
| Debt-to-Equity | N/A |
| Cash Position | $204 thousand |
| Operating Margin | N/A |
| Total Assets | $15,983 thousand |
| Total Debt | $27,584 thousand |
Key Executives
- United States
- People's Republic of China
- Jed Latkin
- Eric Curtis
- Dr. Paul J. McNelis
- Ms. Sarah E. Kelly
- Dr. David J. Glick
- Mr. David M. S. Johnson
- Dr. Craig A. Fraser
- Mr. Michael L. Smith
- Faith L. Charles, Esq.
- Dr. Paul J. Hastings
- Dr. Joseph M. Patti
Industry Context
Windtree Therapeutics operates in the biotechnology sector, a highly competitive and capital-intensive industry. Companies in this space often face long development cycles, significant regulatory hurdles, and the need for substantial funding. Success typically hinges on the development and commercialization of novel therapeutics, often requiring strategic partnerships or acquisitions to scale.
Top Tags
material-agreement (9) · equity-sale (8) · financials (8) · financial-reporting (5) · Biotechnology (4) · SEC Filing (4) · delisting (4) · sec-filing (4) · 8-K (4) · financial-obligation (4)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Cash and cash equivalents | $204 thousand | Decreased from $1,779 thousand at December 31, 2024, indicating severe liquidity issues. |
| Net loss | $(42,761) thousand | Increased significantly from $(4,554) thousand for the nine months ended September 30, 2024, highlighting worsening financial performance. |
| Impairment of intangible assets | $16,130 thousand | A major non-cash expense contributing to the increased net loss for the nine months ended September 30, 2025. |
| Loss on debt issuances | $(22,402) thousand | A significant expense for the nine months ended September 30, 2025, reflecting costly financing activities. |
| Total liabilities | $27,584 thousand | More than doubled from $14,698 thousand at December 31, 2024, indicating a substantial increase in financial obligations. |
| ELOC commitment note payable | $9,443 thousand | A major component of current liabilities at September 30, 2025, up from $328 thousand at December 31, 2024. |
| Derivative liability - ELOC commitment note | $5,089 thousand | Increased significantly from $299 thousand at December 31, 2024, reflecting increased financial risk. |
| Total assets | $15,983 thousand | Decreased from $27,875 thousand at December 31, 2024, indicating asset base erosion. |
| Common stock outstanding | 33,708,784 | As of November 14, 2025, indicating significant share dilution from 256,397 shares at December 31, 2024. |
| Net loss per share attributable to common stockholders (basic and diluted) for Q3 2025 | $(1.08) | Significantly lower than $(211.38) for Q3 2024, but this is due to massive share dilution, not improved performance. |
| Maximum shares registered for resale | $751.8M | Represents potential significant dilution for existing shareholders. |
| Maximum proceeds from ELOC | $50M | Potential capital infusion for the company from Seven Knots. |
| Accumulated deficit as of June 30, 2025 | $861.3M | Indicates substantial historical losses and financial instability. |
| Operating loss for 2024 | $26.1M | Reflects ongoing operational cash burn. |
| Operating loss for 2023 | $20.6M | Shows consistent operational losses year-over-year. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Windtree Therapeutics Inc /De/ (WINTW)?
Windtree Therapeutics Inc /De/ has 50 recent SEC filings from Sep 2024 to Dec 2025, including 35 8-K, 4 10-Q, 4 S-1/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of WINTW filings?
Across 50 filings, the sentiment breakdown is: 9 bearish, 41 neutral. The dominant sentiment is neutral.
Where can I find Windtree Therapeutics Inc /De/ SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Windtree Therapeutics Inc /De/ (WINTW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Windtree Therapeutics Inc /De/?
Key financial highlights from Windtree Therapeutics Inc /De/'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for WINTW?
The investment thesis for WINTW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Windtree Therapeutics Inc /De/?
Key executives identified across Windtree Therapeutics Inc /De/'s filings include United States, People's Republic of China, Jed Latkin, Eric Curtis, Dr. Paul J. McNelis and 8 others.
What are the main risk factors for Windtree Therapeutics Inc /De/ stock?
Of WINTW's 46 assessed filings, 9 were flagged high-risk, 25 medium-risk, and 12 low-risk.
What are recent predictions and forward guidance from Windtree Therapeutics Inc /De/?
Forward guidance and predictions for Windtree Therapeutics Inc /De/ are extracted from SEC filings as they are enriched.